Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?
16/12 04:37
Moderna (NASDAQ:MRNA) stock rallied by close to 20% in Tuesday’s trading, after it announced positive results from mid-stage trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. A combination of the vaccine and Merck’s bl...